Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 8/2010

01-08-2010 | Brief Report

Serum human cartilage glycoprotein-39 in patients with systemic sclerosis: relationship to skin and articular manifestation

Authors: Dominika Wcislo-Dziadecka, Anna Kotulska, Ligia Brzezińska-Wcislo, Malgorzata Widuchowska, Anna Lis-Swiety, Magdalena Kopec-Medrek, Eugene J. Kucharz

Published in: Clinical Rheumatology | Issue 8/2010

Login to get access

Abstract

Human cartilage glycoprotein-39 (HC gp-30) is a secretory protein of several types of cells including chondrocytes. It has been suggested to be a laboratory index of joint damage. Thirty-two patients with systemic sclerosis (SSc) and 22 age-matched controls were investigated. An increased serum HC gp-39 level was shown in SSc patients and was found to correlate with inflammatory indices. There was no correlation with modified Rodnan score, joint involvement, or duration of symptoms of SSc. The obtained results indicate for possible relationship of HCgp-39 to inflammation but do not suggest determination of HC gp-39 as clinically applicable index of articular involvement in SSc patients.
Literature
1.
Blocka KLN (2004) Musculoskeletal involvement in systemic sclerosis. In: Clements PJ, Furst DE (eds) systemic sclerosis. Lippincott Williams and Wilkins, Philadelphia, pp 249–260
2.
Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268:25803–25810PubMed
3.
Wcislo-Dziadecka D, Kotulska A, Kucharz EJ (2005) Human cartilage glycopritein-39, structure, biological role and application in diagnostics. Reumatologia 43:147–153, in Polish
4.
Johansen JS, Kirwan JR, Price PA, Sharif M (2001) Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol 30:297–304CrossRefPubMed
5.
Wcislo-Dziadecka D, Kotulska A, Brzezinska-Wcislo L, Kucharz EJ, Lis-Swiety A, Kaminska-Winciorek G (2009) Serum human cartilage glycoprotein-39 levels in patients with systemic lupus erythematosus. Pol Arch Med Wewn 119:785–788
6.
Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA (1995) Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 31A:1437–1442CrossRefPubMed
7.
La Montagna G, D'Angeli S, Valentini G (2003) Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J Rheumatol 30:2147–2151PubMed
8.
Nordenbaeck C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, Price PA, Jacobsen S (2005) High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheum 34:293–297CrossRef
9.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
10.
Vos K, Steenbakkers P, Miltenburg AMM, Bos E, Van de Heuvel MW, Van Hogezand RA, De Vries RRP, Breedveld FC, Boots AMH (2000) Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 59:544–548CrossRefPubMed
Metadata
Title
Serum human cartilage glycoprotein-39 in patients with systemic sclerosis: relationship to skin and articular manifestation
Authors
Dominika Wcislo-Dziadecka
Anna Kotulska
Ligia Brzezińska-Wcislo
Malgorzata Widuchowska
Anna Lis-Swiety
Magdalena Kopec-Medrek
Eugene J. Kucharz
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1462-y

Other articles of this Issue 8/2010

Clinical Rheumatology 8/2010 Go to the issue

Brief Report

Additional effect of pulsed electromagnetic field therapy on knee osteoarthritis treatment: a randomized, placebo-controlled study

Original Article

Wegener’s granulomatosis: experience from a Brazilian tertiary center

Brief Report

Teaching knee joint aspiration to medical students—an effective training with long-term benefits

Brief Report

Leflunomide in the treatment of patients with early rheumatoid arthritis—results of a prospective non-interventional study

Original Article

Detection of bone erosion in early rheumatoid arthritis: ultrasonography and conventional radiography versus non-contrast magnetic resonance imaging

Review Article

International position paper on febuxostat
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits